Abzena appoints Thomas Castellano as Chief Financial Officer

06th June 2023

San Diego, CA, June 6, 2023 Abzena, the leading end-to-end integrated CDMO for complex biologic molecules and Antibody Drug Conjugates (ADCs) has announced the appointment of Thomas Castellano, as Chief Financial Officer.

Thomas is a proven leader in the CDMO industry, with more than 20 years of experience in corporate finance and capital markets, underpinned by a strong foundation in biotechnology industry finance. He joins Abzena from Catalent, where he spent 15 years in financial leadership roles of increasing responsibility, most recently as the company’s Senior Vice President & Chief Financial Officer.

Tom has previously worked with the capital markets finance group at Lehman Brothers, and began his career at Cendant Corporation as part of its financial leadership development program.

Matt Stober, CEO of Abzena said “I am pleased to welcome Tom to the strong leadership team here at Abzena. Tom’s wealth and breadth of industry relevant financial experience will be valuable as we continue to build on our excellence in bioconjugation and biologics services.

Tom is hugely skilled and experienced in this space, and so him joining our team at Abzena further highlights the strength in our capabilities to help our customers advance their programs, as well as the impressive growth trajectory we are about to embark on.”

Tom Castellano added: “To join Abzena at this stage of the company’s growth provides me with an exciting opportunity. I am delighted to apply my deep experience in the CDMO industry to Abzena, who are moving medicine forward for the benefit of both customers and patients. I look forward to partnering with the leadership team on this new and exciting journey.”

Tom holds a bachelor’s degree in finance and an MBA, both from Seton Hall University, NJ, USA.